Gt Biopharma, INC. (GTBP) — 8-K Filings

All 8-K filings from Gt Biopharma, INC.. Browse 22 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (22)

GT Biopharma Files 8-K for Material Agreement — Apr 7, 2026 Risk: medium
GT Biopharma, Inc. filed an 8-K on April 7, 2026, reporting the entry into a material definitive agreement on April 3, 2026. The filing also includes financial
GT Biopharma Faces Delisting Concerns — Nov 26, 2025 Risk: high
GT Biopharma, Inc. filed an 8-K on November 26, 2025, reporting a notice of delisting or failure to meet continued listing requirements. The filing also include
GT Biopharma Files 8-K on Security Holder Rights — Sep 26, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on September 25, 2025, reporting material modifications to the rights of security holders and financial statements. The company,
GT Biopharma Files 8-K on Security Holder Rights — Sep 23, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on September 23, 2025, reporting events as of September 17, 2025. The filing indicates material modifications to the rights of s
GT Biopharma Reports Director Changes and Officer Compensation — Aug 29, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on August 26, 2025, reporting the departure of director Dr. Jonathan M. Roth and the election of new director Dr. David L. Smith
GT Biopharma Files 8-K on Security Holder Vote — Jul 24, 2025 Risk: low
GT Biopharma, Inc. filed an 8-K on July 24, 2025, to report on the submission of matters to a vote of its security holders. The filing does not contain specific
GT Biopharma Files 8-K on Agreements and Personnel Changes — Jun 11, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on June 11, 2025, reporting on a material definitive agreement, the departure of directors or certain officers, election of dire
GT Biopharma Reports Material Definitive Agreement & Equity Sales — May 27, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on May 27, 2025, reporting on several events that occurred on May 21, 2025. These include entering into a material definitive ag
GT Biopharma Files 8-K on Material Agreements & Equity Sales — May 13, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on May 13, 2025, reporting on several material events as of May 12, 2025. These include entering into a material definitive agre
GT Biopharma Reports Director/Officer Changes — May 5, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on April 29, 2025, reporting changes in its board of directors and executive officers, as well as updates to compensatory arrang
GT Biopharma Reports Unregistered Equity Sales — Apr 4, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on April 4, 2025, reporting unregistered sales of equity securities as of March 31, 2025. The filing also includes financial sta
GT Biopharma Files 8-K on Agreements and Equity Sales — Feb 26, 2025 Risk: medium
GT Biopharma, Inc. filed an 8-K on February 25, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. T
8-K Filing — Jan 27, 2025
GT Biopharma Faces Delisting Concerns — Nov 27, 2024 Risk: high
GT Biopharma, Inc. filed an 8-K on November 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, p
GT Biopharma Files 8-K for Material Agreement — Nov 21, 2024 Risk: medium
GT Biopharma, Inc. filed an 8-K on November 21, 2024, reporting an entry into a material definitive agreement and financial statements. The filing date for the
GT Biopharma Reports Director and Officer Changes — Sep 16, 2024 Risk: medium
GT Biopharma, Inc. filed an 8-K on September 16, 2024, reporting changes in its board of directors and certain officers, as well as updates to compensatory arra
GT Biopharma Files 8-K — Jun 27, 2024 Risk: low
GT Biopharma, Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The company, formerly known as OXIS INTERNATIONAL INC, DDI PH
GT Biopharma Files 8-K on Security Holder Vote Matters — Jun 26, 2024 Risk: medium
GT Biopharma, Inc. filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing indicates a change in the company
GT Biopharma Reports Director/Officer Changes and Compensation — Jun 7, 2024 Risk: medium
GT Biopharma, Inc. filed an 8-K on June 7, 2024, reporting on events that occurred on June 3, 2024. The filing primarily concerns the departure of directors or
GT Biopharma Files 8-K: Material Agreement & Equity Sales — May 23, 2024 Risk: medium
GT Biopharma, Inc. announced on May 21, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity se
GT Biopharma Enters Material Definitive Agreement — Apr 30, 2024 Risk: medium
GT Biopharma, Inc. entered into a Material Definitive Agreement on April 25, 2024. The filing also includes financial statements and exhibits related to this ag
GT Biopharma Files 8-K: Security Holder Rights, Bylaw Amendments — Feb 1, 2024
GT Biopharma, Inc. filed an 8-K on February 1, 2024, to report material modifications to the rights of its security holders and amendments to its Articles of In

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX